A Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) or After Failure of At Least One Prior Multi-Agent Chemotherapy Regimen in Subjects Who Are Not Candidates for ASCT (CHECKMATE)

Trial Profile

A Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) or After Failure of At Least One Prior Multi-Agent Chemotherapy Regimen in Subjects Who Are Not Candidates for ASCT (CHECKMATE)

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms CHECKMATE
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 30 Mar 2016 Status changed from active, no longer recruiting to completed.
    • 02 Sep 2015 Status changed from recruiting to active, no longer recruiting as per United Kingdom Clinical Research Network record.
    • 14 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top